Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers

Gynecologic Oncology

Volumn 101, Issue 1, 2006, Pages 126-131

  Coleman, Robert L ^a   Broaddus, Russell R ^a   Bodurka, Diane C ^a   Wolf, Judith K ^a   Burke, Thomas W ^a   Kavanagh, John J ^a   Levenback, Charles F ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; DIURETIC AGENT; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATINUM DERIVATIVE; STEM CELL FACTOR; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ASCITES; BLOOD TOXICITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EDEMA; FACE EDEMA; FACE RASH; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEG EDEMA; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PATIENT SELECTION; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLE SIZE; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PIPERAZINES; PYRIMIDINES; TAXOIDS;

EID: 33644509244     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.09.041     Document Type: Conference Paper

References (24)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, and A. Ghafoor Cancer statistics, 2005 CA Cancer J. Clin. 55 2005 10 30
2. B.J. Druker, C.L. Sawyers, H. Kantarjian, D.J. Resta, S.F. Reese, and J.M. Ford Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N. Engl. J. Med. 344 2001 1038 1042
3. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, and S. Fanning Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat. Med. 2 1996 561 566
4. P. de Mestier, and G.D. Guetz Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics World J. Surg. 29 2005 357 361
5. S.M. Apte, D. Fan, J.J. Killion, and I.J. Fidler Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma Clin. Cancer Res. 10 2004 897 908
6. A.L. Dewar, A.C. Cambareri, A.C. Zannettino, B.L. Miller, K.V. Doherty, and T.P. Hughes Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib Blood 105 2005 3127 3132
7. D. Matei, D.D. Chang, and M.H. Jeng Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation Clin. Cancer Res. 10 2004 681 690
8. R.E. Schmandt, R. Broaddus, K.H. Lu, H. Shvartsman, A. Thornton, and A. Malpica Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium Cancer 98 2003 758 764
9. M.B. Dabrow, M.R. Francesco, F.X. McBrearty, and S. Caradonna The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium Gynecol. Oncol. 71 1998 29 37
10. A.J. O'Neill, T.G. Cotter, J.M. Russell, and E.F. Gaffney Abl expression in human fetal and adult tissues, tumours, and tumour microvessels J. Pathol. 183 1997 325 329
11. J.A. Parrott, G. Kim, and M.K. Skinner Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer Biol. Reprod. 62 2000 1600 1609
12. A.M. Tonary, E.A. Macdonald, W. Faught, M.K. Senterman, and B.C. Vanderhyden Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis Int. J. Cancer 89 2000 242 250
13. M.A. Versnel, M. Haarbrink, A.W. Langerak, P.A. de Laat, A. Hagemeijer, and T.H. van der Kwast Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo Cancer Genet. Cytogenet. 73 1994 60 64
14. M. Inoue, S. Kyo, M. Fujita, T. Enomoto, and G. Kondoh Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors Cancer Res. 54 1994 3049 3053
15. R. Simon Optimal two-stage designs for phase II clinical trials Control. Clin. Trials 10 1989 1 10
16. E.M. Posadas, M.M. Hussain, H. Kotz, L. Minasian, S.M. Shreeve, and A. Premkumar A phase II clinical trial with proteomic profiling of imatinib mesylate in patients with refractory or relapsed epithelial ovarian cancer (EOC) Proc. Am. Soc. Clin. Oncol. 22 2004 9651
17. B.E. Johnson, T. Fischer, B. Fischer, D. Dunlop, D. Rischin, and S. Silberman Phase II study of imatinib in patients with small cell lung cancer Clin. Cancer Res. 9 2003 5880 5887
18. K. Rao, S. Goodin, M.J. Levitt, N. Dave, W.J. Shih, and Y. Lin A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer Prostate 62 2005 115 122
19. S.J. Hotte, E.W. Winquist, E. Lamont, M. MacKenzie, E. Vokes, and E.X. Chen Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study J. Clin. Oncol. 23 2005 585 590
20. V.A. Holst, C.E. Marshall, C.A. Moskaluk, and H.F. Frierson Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma Mod. Pathol. 12 1999 956 960
21. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J. Clin. Invest. 111 2003 1287 1295
22. G.C. Jayson, G.J. Parker, S. Mullamitha, J.W. Valle, M. Saunders, and L. Broughton Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume J. Clin. Oncol. 23 2005 973 981
23. M. Debiec-Rychter, H. Dumez, I. Judson, B. Wasag, J. Verweij, and M. Brown Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 40 2004 689 695
24. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139